NASDAQ:ESRX - Express Scripts Stock Price, Price Target & More

$74.55 +1.06 (+1.44 %)

(As of 04/23/2018 11:36 AM ET)

Previous Close$73.49

Today's Range$72.88 - $74.66

52-Week Range$55.80 - $85.07

Volume1.16 million shs

Average Volume5.03 million shs

Market Capitalization$41.27 billion

P/E Ratio10.35

Dividend YieldN/A

Beta0.99

About Express Scripts (NASDAQ:ESRX)

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores

Sub-IndustryHealth Care Services

SectorMedical

SymbolNASDAQ:ESRX

CUSIP30219G10

Webwww.express-scripts.com

Phone314-996-0900

Debt

Debt-to-Equity Ratio0.83%

Current Ratio0.67%

Quick Ratio0.55%

Price-To-Earnings

Trailing P/E Ratio10.35

Forward P/E Ratio8.00

P/E Growth0.9

Sales & Book Value

Annual Sales$100.06 billion

Price / Sales0.42

Cash Flow$10.6348 per share

Price / Cash7.01

Book Value$32.00 per share

Price / Book2.33

Profitability

EPS (Most Recent Fiscal Year)$7.10

Net Income$4.52 billion

Net Margins4.51%

Return on Equity25.19%

Return on Assets8.00%

Miscellaneous

Employees26,600

Outstanding Shares561,530,000

How to Become a New Pot Stock Millionaire

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts declared that its board has authorized a share repurchase program on Wednesday, December 20th 2017, which allows the company to repurchase 45,000,000 shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts (NASDAQ:ESRX) announced its quarterly earnings results on Tuesday, February, 27th. The company reported $2.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.09 by $0.07. The firm earned $25.38 billion during the quarter, compared to analysts' expectations of $25.07 billion. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.88 EPS. View Express Scripts' Earnings History.

When is Express Scripts' next earnings date?

Express Scripts is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $9.27-9.47 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.93. Express Scripts also updated its Q1 guidance to $1.73-1.78 EPS.

What price target have analysts set for ESRX?

19 analysts have issued 1-year target prices for Express Scripts' stock. Their predictions range from $57.00 to $101.00. On average, they expect Express Scripts' share price to reach $81.8214 in the next twelve months. View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:

1. According to Zacks Investment Research, "Integrating medical care and pharmacy benefits under one roof, Express Scripts Holding Company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company.The company has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. The company recently inked an agreement to acquire eviCore healthcare for $3.6 billion. Express Scripts' pharmacy-benefit management segment (PBM) coupled with eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. On the flip side, the company recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. The company faces stiff competition." (3/13/2018)
2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)

Are investors shorting Express Scripts?

Express Scripts saw a decline in short interest in March. As of March 15th, there was short interest totalling 19,241,219 shares, a decline of 20.8% from the February 28th total of 24,284,790 shares. Based on an average trading volume of 8,958,251 shares, the short-interest ratio is currently 2.1 days. Currently, 3.4% of the shares of the stock are sold short.

Who are some of Express Scripts' key competitors?

Some companies that are related to Express Scripts include CSL (CSL), Celgene (CELG), GlaxoSmithKline (GSK), Becton Dickinson (BDX), Stryker (SYK), Aetna (AET), Anthem (ANTM), Biogen (BIIB), Allergan (AGN), Intuitive Surgical (ISRG), Shire (SHPG), Fresenius (FSNUY), Zoetis (ZTS), Beximco Pharmaceuticals (BXP), Humana (HUM), Vertex Pharmaceuticals (VRTX), Boston Scientific (BSX) and Baxter International (BAX).

Who are Express Scripts' key executives?

Express Scripts' management team includes the folowing people:

Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
Mr. Neal Sample, Exec. VP & COO (Age 43)
Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
Ms. Christine Houston, Exec. VP (Age 55)
Mr. Eric R. Slusser, Exec. Officer (Age 57)

Has Express Scripts been receiving favorable news coverage?

Headlines about ESRX stock have been trending somewhat negative recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Express Scripts earned a media sentiment score of -0.02 on Accern's scale. They also assigned media coverage about the company an impact score of 46.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Express Scripts?

Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of ESRX stock can currently be purchased for approximately $74.44.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $41.27 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, ST. LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]

MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		694 (Vote Outperform)
Underperform Votes:		485 (Vote Underperform)
Total Votes:		1,179

MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Express Scripts (NASDAQ:ESRX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Express Scripts in the last 12 months. Their average twelve-month price target is $81.8214, suggesting that the stock has a possible upside of 9.75%. The high price target for ESRX is $101.00 and the low price target for ESRX is $57.00. There are currently 3 sell ratings, 11 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.11	2.10	2.14	2.00
Ratings Breakdown:	3 Sell Rating(s) 11 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 12 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 10 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 11 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$81.8214	$81.8214	$77.8571	$69.2308
Price Target Upside:	9.75% upside	1.33% upside	2.79% downside	13.20% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/12/2018	Sanford C. Bernstein	Upgrade	Underperform -> Market Perform		Medium
3/9/2018	Wells Fargo	Upgrade	Underperform -> Market Perform		Low
3/8/2018	Raymond James	Upgrade	Underperform -> Market Perform		Low
3/8/2018	Mizuho	Set Price Target	Hold	$96.00	Low
3/8/2018	William Blair	Downgrade	Outperform -> Market Perform		Low
3/8/2018	Jefferies Group	Downgrade	Buy -> Hold	$91.00	High
3/8/2018	Maxim Group	Downgrade	Buy -> Hold		High
3/8/2018	Barclays	Initiated Coverage	Equal Weight -> Equal Weight	$84.00	High
2/27/2018	Bank of America	Initiated Coverage	Underperform -> Underperform	$77.00	Medium
1/31/2018	Royal Bank of Canada	Upgrade	Sector Perform -> Outperform	$68.00	Low
1/12/2018	SunTrust Banks	Reiterated Rating	Buy	$95.00	Low
1/9/2018	Robert W. Baird	Reiterated Rating	Outperform -> Buy	$81.00 -> $92.00	N/A
1/4/2018	Evercore ISI	Initiated Coverage	In -> In-Line	$78.00	Low
12/21/2017	Needham & Company LLC	Reiterated Rating	Hold		Low
12/4/2017	Deutsche Bank	Initiated Coverage	Buy	$75.00	High
10/9/2017	UBS	Downgrade	Market Perform -> Underperform		N/A
8/10/2017	Morgan Stanley	Boost Price Target	Underweight	$52.00 -> $57.00	Low
6/9/2017	Cowen	Reiterated Rating	Outperform	$83.00	Low
4/26/2017	Edward Jones	Downgrade	Buy -> Hold		High
3/29/2017	Argus	Reiterated Rating	Hold		Low
3/8/2017	Leerink Swann	Reiterated Rating	Market Perform	$75.00	Low
2/16/2017	Credit Suisse Group	Reiterated Rating	Buy	$85.00	N/A
2/14/2017	Oppenheimer	Reiterated Rating	Hold		N/A
6/1/2016	Wedbush	Reiterated Rating	Neutral		N/A
5/24/2016	Citigroup	Reiterated Rating	Buy		N/A
4/27/2016	FBR & Co	Lower Price Target	Mkt Perform	$90.00 -> $75.00	N/A

(Data available from 4/23/2016 forward)

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2018 EPS Consensus Estimate: $9.06
2019 EPS Consensus Estimate: $9.65

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$1.46	$1.76	$1.69
Q2 2018	5	$1.90	$2.39	$2.22
Q3 2018	5	$2.09	$2.57	$2.43
Q4 2018	5	$2.31	$2.88	$2.71
Q1 2019	3	$1.58	$2.10	$1.87
Q2 2019	3	$2.09	$2.48	$2.32
Q3 2019	3	$2.26	$2.67	$2.53
Q4 2019	2	$2.88	$2.97	$2.93

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018		$1.76					N/A
4/23/2018		$1.75					N/A
2/27/2018	Q4 2017	$2.09	$2.16	$25.0710 billion	$25.3790 billion	View	N/A
10/24/2017	Q3 2017	$1.90	$1.90	$25.6827 billion	$24.6834 billion	View	N/A
7/25/2017	Q2 2017	$1.71	$1.73	$25.5249 billion	$25.3475 billion	View	N/A
4/24/2017	Q1 17	$1.32	$1.33	$24.9516 billion	$24.6549 billion	View	N/A
2/14/2017	Q4 2016	$1.8660	$1.88	$26.31 billion	$24.90 billion	View	Listen
10/25/2016	Q3	$1.74	$1.74	$25.4846 billion	$25.41 billion	View	Listen
7/25/2016	Q216	$1.57	$1.57	$25.42 billion	$25.20 billion	View	Listen
4/25/2016	Q1	$1.22	$1.22	$25.20 billion	$24.80 billion	View	Listen
2/16/2016	Q4	$1.56	$1.56	$26.58 billion	$26.18 billion	View	Listen
10/27/2015	Q315	$1.44	$1.45	$26.38 million	$25.22 million	View	Listen
7/28/2015	Q215	$1.40	$1.44	$26.13 billion	$25.4540 billion	View	Listen
4/28/2015	Q115	$1.10	$1.10	$24.34 billion	$24.90 billion	View	Listen
2/23/2015	Q414	$1.38	$1.39	$25.68 billion	$26.31 billion	View	Listen
10/28/2014	Q314	$1.29	$1.29	$24.93 billion	$25.78 billion	View	Listen
7/29/2014	Q214	$1.22	$1.23	$24.42 billion	$25.1110 billion	View	Listen
4/29/2014	Q114	$1.01	$0.99	$23.81 billion	$23.6850 billion	View	Listen
2/20/2014	Q413	$1.12	$1.12	$25.49 billion	$25.78 billion	View	N/A
10/25/2013	Q313	$1.08	$1.08	$25.01 billion	$25.9160 billion	View	Listen
7/29/2013	Q2 2013	$1.10	$1.12	$25.51 billion	$26.40 billion	View	Listen
4/29/2013	Q1 2013	$0.97	$0.99	$25.55 billion	$26.0630 billion	View	Listen
2/18/2013	Q4 2012	$1.04	$1.05	$27.24 billion	$27.41 billion	View	Listen
11/5/2012	Q312	$0.99	$1.02	$27.48 billion	$27.00 billion	View	N/A
8/7/2012		$0.82	$0.88			View	N/A
5/10/2012		$0.77	$0.73			View	N/A
2/22/2012		$0.85	$0.82			View	N/A
10/25/2011		$0.77	$0.79			View	N/A
7/21/2011		$0.69	$0.71			View	N/A
4/26/2011		$0.69	$0.66			View	N/A
2/16/2011		$0.70	$0.71			View	N/A
10/27/2010	Q3 2010	$0.65	$0.65			View	N/A
7/28/2010	Q2 2010	$0.59	$0.60			View	N/A
4/28/2010	Q1 2010	$0.55	$0.55			View	N/A
2/24/2010	Q4 2009	$0.45	$0.49			View	N/A
10/28/2009	Q3 2009	$0.41	$0.40			View	N/A
7/29/2009	Q2 2009	$0.44	$0.44			View	N/A
4/29/2009	Q1 2009	$0.41	$0.43			View	N/A
2/25/2009	Q4 2008	$0.42	$0.41			View	N/A
10/30/2008	Q3 2008	$0.39	$0.41			View	N/A
7/30/2008	Q2 2008	$0.36	$0.38			View	N/A
4/29/2008	Q1 2008	$0.34	$0.35			View	N/A
2/21/2008	Q4 2007	$0.32	$0.34			View	N/A

(Earnings results data provided by Zacks Investment Research)

Express Scripts (NASDAQ:ESRX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 89.29%

Insider Trading History for Express Scripts (NASDAQ:ESRX)

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2018	Christine Houston	Insider	Sell	19,889	$76.69	$1,525,287.41
3/1/2018	Everett Neville	VP	Sell	4,895	$75.26	$368,397.70
1/11/2018	Glen D Stettin	VP	Sell	3,449	$81.00	$279,369.00	33,715
1/2/2018	Glen D Stettin	VP	Sell	3,448	$76.00	$262,048.00
12/15/2017	Christine Houston	VP	Sell	10,104	$70.08	$708,088.32	87,400
11/1/2017	Phyllis S. Anderson	VP	Sell	643	$62.37	$40,103.91
10/31/2017	Timothy C Wentworth	CEO	Buy	8,000	$61.13	$489,040.00	98,628
9/11/2017	Woodrow A Myers Jr	Director	Sell	3,900	$63.93	$249,327.00	11,500
9/8/2017	Phyllis S Anderson	VP	Sell	578	$63.13	$36,489.14	10,530
8/23/2017	Everett Neville	VP	Sell	1,163	$61.48	$71,501.24	18,232
5/19/2017	Phyllis S Anderson	VP	Sell	1,100	$60.08	$66,088.00	11,108
3/1/2017	Everett Neville	SVP	Sell	2,352	$70.16	$165,016.32	11,287
1/3/2017	Everett Neville	VP	Sell	1,123	$69.41	$77,947.43	12,712
9/14/2016	Woodrow A Myers Jr	Director	Sell	12,036	$70.40	$847,334.40	14,918
9/12/2016	Christopher A Mcginnis	VP	Sell	1,785	$70.77	$126,324.45	4,955
5/10/2016	Everett Neville	VP	Sell	800	$74.11	$59,288.00	13,835
4/29/2016	Mahon Thomas P Mac	Director	Sell	5,482	$73.93	$405,284.26	55,689
3/10/2016	Christopher A Mcginnis	VP	Sell	579	$68.56	$39,696.24	6,508
3/7/2016	Phyllis S Anderson	VP	Sell	614	$71.14	$43,679.96	4,346
2/29/2016	Everett Neville	VP	Sell	4,323	$71.00	$306,933.00	11,126
6/9/2015	Gary Wimberly	VP	Sell	1,644	$87.14	$143,258.16
6/1/2015	Gary Wimberly	VP	Sell	46,069	$86.15	$3,968,844.35
3/2/2015	Glen D Stettin	VP	Sell	2,674	$84.39	$225,658.86
2/25/2015	Glen D Stettin	VP	Sell	27,603	$87.55	$2,416,642.65
12/2/2014	Keith J Ebling	VP	Sell	10,000	$84.25	$842,500.00
12/1/2014	Steven B Miller	VP	Sell	4,896	$83.57	$409,158.72
11/28/2014	Glen D Stettin	VP	Sell	10,800	$82.96	$895,968.00
11/17/2014	John O Parker	Director	Sell	25,822	$78.75	$2,033,482.50
11/7/2014	Maura C Breen	Director	Sell	13,128	$77.80	$1,021,358.40
9/5/2014	Edward B Ignaczak	EVP	Sell	9,886	$75.28	$744,218.08
8/28/2014	Seymour Sternberg	Director	Sell	15,508	$74.12	$1,149,452.96
8/25/2014	Keith J Ebling	VP	Sell	10,000	$75.50	$755,000.00
8/5/2014	Gary G Benanav	Director	Sell	12,694	$70.82	$898,989.08
8/5/2014	Sara E Wade	VP	Sell	20,000	$70.44	$1,408,800.00
8/4/2014	David A Norton	VP	Sell	1,276	$71.02	$90,621.52
8/1/2014	Maura C Breen	Director	Sell	12,694	$69.94	$887,818.36
6/13/2014	George Paz	CEO	Sell	681,508	$71.21	$48,530,184.68
3/11/2014	Keith Ebling	VP	Sell	25,721	$78.69	$2,023,985.49	22,222
3/10/2014	Patrick Mcnamee	COO	Sell	68,425	$78.28	$5,356,309.00	12,421
3/10/2014	Steven Miller	VP	Sell	12,664	$77.96	$987,285.44	21,417
3/7/2014	Keith Ebling	VP	Sell	295,367	$77.29	$22,828,915.43	28,460
1/9/2014	Nicholas Lahowchic	Director	Sell	7,650	$72.00	$550,800.00	24,903
12/26/2013	Nicholas Lahowchic	Director	Sell	12,694	$70.00	$888,580.00	24,903
11/5/2013	Mahon Thomas Mac	Director	Sell	10,251	$63.20	$647,863.20	39,881
9/9/2013	Maura C Breen	Director	Sell	10,527	$64.12	$674,991.24
9/4/2013	Woodrow Myers, Jr.	Director	Sell	7,128	$64.66	$460,896.48	9,698
7/19/2013	Nicholas Lahowchic	Director	Sell	20,377	$66.26	$1,350,180.02
6/11/2013	Woodrow A Myers Jr	Director	Sell	1,750	$62.57	$109,497.50
5/28/2013	Woodrow A Myers Jr	Director	Sell	2,000	$63.75	$127,500.00
5/15/2013	Jeffrey Hall	CFO	Sell	13,307	$61.13	$813,456.91
5/8/2013	Woodrow A Myers Jr	Director	Sell	13,462	$61.22	$824,143.64
5/1/2013	Keith J Ebling	EVP	Sell	59,494	$59.58	$3,544,652.52
4/30/2013	Patrick Mcnamee	COO	Sell	271,972	$59.65	$16,223,129.80
3/14/2013	Mahon Thomas P Mac	Director	Buy	5,000	$59.58	$297,900.00
9/4/2012	Jeffrey Hall	CFO	Sell	75,000	$62.81	$4,710,750.00
8/8/2012	Edward B Ignaczak	EVP	Sell	115,466	$59.33	$6,850,597.78

(Data available from 1/1/2013 forward)

Express Scripts (NASDAQ ESRX) News Headlines

Source:

Date	Headline
	Fight against opioids impacts workers' comp spending, myMatrixx report finds finance.yahoo.com - April 23 at 8:01 AM
	Express Scripts (ESRX) Downgraded by BidaskClub to Sell www.americanbankingnews.com - April 19 at 11:34 AM
	Cigna-Express Scripts Deal to Face Justice Department Review finance.yahoo.com - April 19 at 8:05 AM
	How Is UNH’s Optum Business Positioned in the Industry? finance.yahoo.com - April 17 at 8:03 AM
	Express Scripts (ESRX) Expected to Announce Quarterly Sales of $24.76 Billion www.americanbankingnews.com - April 16 at 4:00 AM
	Express Scripts (ESRX) Scheduled to Post Earnings on Monday www.americanbankingnews.com - April 16 at 3:46 AM
	Brokerages Expect Express Scripts (ESRX) Will Post Earnings of $1.76 Per Share www.americanbankingnews.com - April 14 at 9:19 AM
	Express Scripts Holding Company Announces First Quarter 2018 Earnings Release Details feeds.benzinga.com - April 13 at 3:36 PM
	Express Scripts launches innovative pilot program for performance-based retail pharmacy network seekingalpha.com - April 12 at 5:59 PM
	Is Express Scripts Holding Company’s (NASDAQ:ESRX) Balance Sheet Strong Enough To Weather A Storm? finance.yahoo.com - April 12 at 5:59 PM
	Head to Head Survey: Express Scripts (ESRX) and HealthWarehouse.com (HEWA) www.americanbankingnews.com - April 12 at 9:33 AM
	Express Scripts to close Ohio site, lay off 456 www.bizjournals.com - April 11 at 5:54 PM
	Express Scripts to close Columbus site, lay off 456 www.bizjournals.com - April 10 at 5:46 PM
	Profit From Record Q1 M&A With These ETFs finance.yahoo.com - April 10 at 5:46 PM
	U.S. Workers' Compensation Prescription Drug Spending Decreased 3.3 Percent in 2017 finance.yahoo.com - April 10 at 8:04 AM
	Express Scripts (ESRX) Upgraded by ValuEngine to Buy www.americanbankingnews.com - April 8 at 12:54 PM
	Robert W. Baird Boosts Express Scripts (ESRX) Price Target to $59.00 www.americanbankingnews.com - April 5 at 2:27 PM
	Express Scripts (ESRX) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 5 at 12:10 PM
	Analyzing Walgreens Boots Alliance (WBA) & Express Scripts (ESRX) www.americanbankingnews.com - April 5 at 9:31 AM
	Royal Bank of Canada Analysts Give Express Scripts (ESRX) a $66.00 Price Target www.americanbankingnews.com - April 4 at 9:36 PM
	Express Scripts Appoints New CIO from Farmers Insurance finance.yahoo.com - April 4 at 4:30 PM
	Ohio regulator orders insurers, benefit managers to give lowest drug price finance.yahoo.com - April 4 at 4:30 PM
	Head to Head Contrast: Walgreens Boots Alliance (WBA) & Express Scripts (ESRX) www.americanbankingnews.com - April 4 at 3:38 PM
	Express Scripts Names Ron Guerrier Chief Information Officer finance.yahoo.com - April 3 at 5:49 PM
	Express Scripts (ESRX) Downgraded by ValuEngine to "Hold" www.americanbankingnews.com - April 3 at 4:16 PM
	Critical Comparison: Express Scripts (ESRX) & Rite Aid (RAD) www.americanbankingnews.com - April 3 at 1:42 PM
	Express Scripts Names Mike Cirillo President of myMatrixx finance.yahoo.com - April 2 at 5:42 PM
	Q1 Witnesses Consolidation Wave With All-Time High Global M&A finance.yahoo.com - April 2 at 8:00 AM
	MARKETS: FANG stocks and chipmakers are set to close Q1 with a bang—maybe even AMZN finance.yahoo.com - March 31 at 5:44 PM
	Express Scripts Holding (ESRX) Expected to Announce Quarterly Sales of $24.76 Billion www.americanbankingnews.com - March 30 at 3:04 AM
	Express Scripts (ESRX) Rating Reiterated by Robert W. Baird www.americanbankingnews.com - March 30 at 12:56 AM
	Why Is Express Scripts Holding Company (ESRX) Down 10.5% Since its Last Earnings Report? finance.yahoo.com - March 29 at 5:44 PM
	Short Interest in Express Scripts Holding (ESRX) Drops By 20.8% www.americanbankingnews.com - March 29 at 3:10 AM
	Why Express Scripts Stock Could Improve From Here finance.yahoo.com - March 28 at 5:35 PM
	CareCentrix, Inc. -- Moody's affirms CareCentrix's B1 ratings; changes outlook to stable finance.yahoo.com - March 28 at 5:35 PM
	$1.77 EPS Expected for Express Scripts Holding (ESRX) This Quarter www.americanbankingnews.com - March 28 at 9:16 AM
	Is Express Scripts Holding Company (NASDAQ:ESRX) A Buy At Its Current PE Ratio? finance.yahoo.com - March 28 at 8:06 AM
	Here’s the Truth About Express Scripts Holding Co Stock and PBMs investorplace.com - March 28 at 7:16 AM
	Pre-Market Technical Scan on Health Care Plans Equities -- Centene, Cigna, CVS Health, and Express Scripts www.prnewswire.com - March 27 at 8:04 AM
	Cigna (CI) to Acquire Express Scripts (ESRX) for $67 Billion www.streetinsider.com - March 26 at 5:36 PM
	Express Scripts (ESRX) Upgraded to Outperform at Royal Bank of Canada www.americanbankingnews.com - March 26 at 11:34 AM
	Express Scripts (ESRX) Receives New Coverage from Analysts at Bank of America www.americanbankingnews.com - March 24 at 9:28 PM
	Express Scripts (ESRX) PT Set at $91.00 by Jefferies Group www.americanbankingnews.com - March 24 at 5:46 PM
	Trader hopes Express Scripts gets better www.nasdaq.com - March 24 at 5:30 PM
	Should Value Investors Pick Express Scripts Holding (ESRX)? finance.yahoo.com - March 21 at 5:54 PM
	Cigna CEO: Express Scripts deal 'a broadening of capabili... finance.yahoo.com - March 20 at 8:05 AM
	Cigna and Express Scripts: Cramer's Top Takeaways finance.yahoo.com - March 20 at 8:05 AM
	Don't Turn Your Back on This Market: Cramer's 'Mad Money' Recap (Monday 3/19/18) finance.yahoo.com - March 20 at 8:05 AM
	Express Scripts Holding (ESRX) Insider Sells $1,525,287.41 in Stock www.americanbankingnews.com - March 19 at 7:15 PM
	Financial Comparison: Express Scripts (ESRX) & Its Peers www.americanbankingnews.com - March 19 at 11:51 AM

Express Scripts (NASDAQ:ESRX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Express Scripts (NASDAQ ESRX) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff